Therapeutics
Search By Attributes
Search Results
| Name | Synonyms | FDA Status | Company | Target Type | Therapy Type | Approved For |
|---|---|---|---|---|---|---|
| AAV2-BDNF | MCI due to AD (Phase 1), Alzheimer's Disease (Phase 1) | Other | DNA/RNA-based | |||
| ALN-APP | Alzheimer's Disease (Phase 1) | Alnylam Pharmaceuticals, Inc., Regeneron Pharmaceuticals Inc. | Amyloid-Related | DNA/RNA-based | ||
| BIIB080 | IONIS-MAPTRx, ISIS 814907 |
Alzheimer's Disease (Phase 1) | Biogen, IONIS Pharmaceuticals | Tau | DNA/RNA-based | |
| CpG 1018® | CpG oligodeoxynucleotides, CpG ODN |
Alzheimer's Disease (Phase 1) | Dynavax Technologies | Amyloid-Related, Inflammation | Immunotherapy (active), DNA/RNA-based | |
| LX1001 | AAVrh.10-APOE2, AAVrh.10hAPOE2 |
Alzheimer's Disease (Phase 1) | Lexeo Therapeutics | Amyloid-Related | DNA/RNA-based | |
| NIO752 | Progressive Supranuclear Palsy (Phase 1), Alzheimer's Disease (Phase 1) | Novartis Pharmaceuticals Corporation | Tau | DNA/RNA-based |